Chinese patent medicine for treating aplastic anemia

A technology of aplastic and Chinese patent medicines, which can solve many problems such as blood diseases, drug combinations, and medical formulas.

Active Publication Date: 2011-12-14
魏兴禹
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are many literature reports on Chi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] The Chinese patent medicine for treating aplastic anemia of the present invention is expressed in parts by weight. The raw materials of the Chinese patent medicine are composed of 15 g of Rehmannia glutinosa, 20 g of Scrophulariae Radix, 15 g of Ophiopogon japonicus, 12 g of Alisma, 10 g of mulberry leaves, 15 g of madder, 10 g of gardenia, and Cortex Moutan 10g, 20g of Rhizoma Imperatae. The prescription of the Chinese patent medicine is used for treating aplastic anemia of yin deficiency type.

[0076] The dosage form of the above-mentioned Chinese patent medicine for treating aplastic anemia of the present invention is water pill or decoction with water.

[0077] The preparation method of the water pill is as follows: firstly, various raw materials are screened, cleaned of impurities, moldy and eroded, and then the processed raw materials are weighed according to the above-mentioned raw material ratio of the Chinese patent medicine for treating aplastic anemia. For ...

Embodiment 2

[0079] Embodiment 2: basically the same as Embodiment 1, the difference is:

[0080] The Chinese patent medicine for treating aplastic anemia of the present invention is expressed in parts by weight, and the raw materials of the Chinese patent medicine are composed of 12 g of Rehmannia glutinosa, 20 g of Scrophulariae Radix, 15 g of Ophiopogon japonicus, 12 g of Alisma, 9 g of mulberry leaves, 15 g of madder, 15 g of gardenia, and Moutan bark 12g, 30g of coriander root. The prescription of the Chinese patent medicine is used for treating aplastic anemia of yin deficiency type.

Embodiment 3

[0081] Embodiment 3: basically the same as Embodiment 1, the difference is:

[0082] The Chinese patent medicine for treating aplastic anemia of the present invention is expressed in parts by weight. The raw materials of the Chinese patent medicine are composed of 6 grams of Rehmannia glutinosa, 10 grams of Radix Scrophulariae, 9 grams of Ophiopogon japonicus, 6 grams of Alisma, 6 grams of mulberry leaves, and 9 grams of madder, Gardenia 10 grams, Moutan bark 6 grams, Imperata 15 grams. The prescription of the Chinese patent medicine is used for treating aplastic anemia of yin deficiency type.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a Chinese patent medicament for treating aplastic anemia. The Chinese patent medicament comprises the following Chinese herbal medicines: prepared rehmannia root, figwort root, dwarf lilyturf tuber, oriental waterplantain rhizome, mulberry, India madder root, gardenia, tree paeony bark, lalang grass rhizome and the like. The Chinese patent medicament contains fewer ingredients according to a formula, is mixed scientifically, does not have toxic or side effect, and has an obvious treatment effect on acute and chronic aplastic anemia. By the treatment with the Chinese patent medicament, the effective rate of the aplastic anemia is over 90 percent, and the cure rate is over 80 percent. The Chinese patent medicament has a good clinical treatment effect on aplastic anemia and has the high safety of clinical administration, and bone marrow transplantation is prevented, so the treatment cost is low.

Description

technical field [0001] The invention relates to a Chinese patent medicine, in particular to a Chinese patent medicine for treating aplastic anemia. Background technique [0002] Aplastic anemia has a high incidence rate in recent years. Aplastic anemia is referred to as aplastic anemia. It is due to a variety of reasons that cause a significant decrease in bone marrow hematopoietic tissue and bone marrow hematopoietic failure. Typical symptoms are: progressive anemia, bleeding, infection and whole blood cells In traditional Chinese medicine, it belongs to the category of "consumption of deficiency and blood disease". The disease is generally caused by factors such as chemistry, treatment, and infection. Symptoms, and fever is easy to repeat, skin has bleeding points, pale tongue, thin white fur, deep thready or thready pulse, and some patients have gum infection, anorectal inflammation, dry and itchy throat, etc. The main feature of the hemogram during aplastic anemia is pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/899A61P7/06
Inventor 魏如庆魏兴禹黄杰
Owner 魏兴禹
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap